Screener
Jazz Pharmaceuticals JAZZ Current Debt
Current Debt at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.
The source filing: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001232524-26-000025
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $100.0 | $122.1 |
| Accrued liabilities | 1,022.4 | 1,034.2 |
| Current portion of long-term debt | 1,030.5 | 1,029.9 |
| Income taxes payable | 93.7 | 56.3 |
| Total current liabilities | 2,246.6 | 2,242.5 |
| Long-term debt, less current portion | 4,324.2 | 4,328.4 |
| Operating lease liabilities, less current portion | 47.3 | 50.9 |
Item 1.Financial Statements
FAQ
- What is Jazz Pharmaceuticals's current debt?
- Jazz Pharmaceuticals (JAZZ) reported current debt of $1.03B in Q1 2026.
- How has Jazz Pharmaceuticals's current debt changed year-over-year?
- Jazz Pharmaceuticals's current debt increased by 3224.2% year-over-year, from $31M to $1.03B.
- What is the long-term trend for Jazz Pharmaceuticals's current debt?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's current debt has grown at a 33.1% compound annual growth rate (CAGR), from $246.32M to $1.03B.
- What does current debt mean?
- The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.
Ask your AI about Jazz Pharmaceuticals's current debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude